Phaseline

Companies › Treadwell Therapeutics

Treadwell Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 8 registered trials: 5 Phase 2, 3 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CFI-400945
Serine/threonine-protein kinase PLK4 inhibitor
PLK4Phase 1Acute Myeloid Leukemia; Prostate Cancer; Breast Cancer–
CFI-402257
TTK inhibitor
TTKPhase 1Advanced Solid Tumor; Breast Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03385655CFI-400945Phase 2Prostate CancerOncologyOct 2024
NCT04730258CFI-400945Phase 1Acute Myeloid LeukemiaOncologyJan 2026
NCT05251714CFI-402257Phase 1Advanced Solid TumorOncologyAug 2026
NCT03624543CFI-400945Phase 2Breast CancerOncologyNov 2026
NCT03568422CFI-402257Phase 1Breast CancerOncologyDec 2026
NCT04176848CFI-400945Phase 2Breast CancerOncologyDec 2026
NCT05601440CFI-402257Phase 2Breast CancerOncologyDec 2027
NCT05601440CFI-400945Phase 2Breast CancerOncologyDec 2027

Targets

TTK (1) PLK4 (1)

Companies with the same targets

SillaJen

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.